Prof. Allen Seftel: be part of new innovations
Meet the Professor

Prof. Allen Seftel: be part of new innovations


Submitted May 26, 2016. Accepted for publication May 27, 2016.

doi: 10.21037/tau.2016.06.01


The 2016 American Urological Association Annual Meeting was held grandly in the San Diego Convention Center, USA from May 6th to 10th. During the annual meeting, many news researches were shared and discussed. This time, the Editorial Office of Translational Andrology and Urology (TAU) was honored to invite Prof. Allen Seftel (Figure 1), from Cooper University Hospital, to have an interview with us.

Figure 1 Picture with Prof. Allen Seftel.

In the interview, Prof. Seftel described some of the advantages of non-surgical therapy for Benign Prostatic Hyperplasia compared to surgical therapy as well as the situation when surgery is an appropriate choice.

As the only urologist and sexual health expert included on the American Heart Association’s writing panel, Prof. Seftel shared with us his idea on the previously published statement on “Sexual Activity and Cardiovascular Disease” and introduced the relationship between sexual activity and cardiovascular disease.

To our young generation who’re going to be urologists, Prof. Seftel gave some of his advices: try to have highlights of interest and be part of new innovations!

At the end, Prof. Seftel also told us his preference if he was not an urologist—a researcher to find new technology, new surgery, and new treatment options (Figure 2)!

Figure 2 Prof. Allen Seftel: be part of new innovations (1). Available online: http://www.asvide.com/articles/1070

Interview questions

  • You have previously joined the session about “Benign Prostatic Hyperplasia: Medical & Non-surgical Therapy”. Here would you like to share with us what’s advantages of non-surgical therapy for BPH compared to surgical therapy?
  • Do you think the non-surgical therapy will be a popular choice for patients in the future?
  • When will surgery for BPH be an appropriate choice?
  • We know that you’re the only urologist and sexual health expert included on the American Heart Association’s writing panel. It previously released a groundbreaking scientific statement “Sexual Activity and Cardiovascular Disease”. Would you like to share with us your idea on this statement? What do you think the relationship between sexual activity and cardiovascular disease?
  • How do you think urologist should work with cardiac surgeon for the benefit of patient?
  • You are quite an expert in urology and have worked in this field for many years. Then what do you think the changes or progress on the treatment in urology in the past few years?
  • As an experienced urologist, would you like to share with us some advice to our young generation who’re going to be urologists? Innovation.
  • What will you do if you were not an urologist?

Expert introduction

Allen Seftel well published in his field and speaks frequently about male sexual function in the USA and internationally. He is distinguished as the only urologist and sexual health expert included on the American Heart Association’s writing panel that recently released the groundbreaking scientific statement “Sexual Activity and Cardiovascular Disease”.

Prof. Seftel recently took part in a Point-Counterpoint session at the American Urological Association 2013 Annual Meeting regarding identifying cardiovascular risk in patients with erectile dysfunction.

His interest includes Male sexual medicine, male sexual function, male infertility, benign prostatic hyperplasia, testosterone deficiency in men, Peyronie’s disease, penile-rehabilitation post-prostate cancer treatment, kidney and ureteral stone removal.


Acknowledgements

None.


Footnote

Conflicts of Interest: The author has no conflicts of interest to declare.


References

  1. Gao S. Prof. Allen Seftel: be part of new innovations. Asvide 2016;3:298. Available online: http://www.asvide.com/articles/1070

(Science Editor: Skylar Gao, TAU, tau@amepc.org)

Cite this article as: Gao S. Prof. Allen Seftel: be part of new innovations. Transl Androl Urol 2016;5(4):624-625. doi: 10.21037/tau.2016.06.01